Published in Medical Letter on the CDC and FDA, November 6th, 2005
The approval was based on the Intergroup Exemestane Study (IES) which showed that patients who switched to Aromasin after 2-3 years of tamoxifen, for a combined total of 5 years of therapy, had 31% more protection from cancer recurrence than those who remained on 5 years of tamoxifen therapy.
This landmark study, published in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA